Volatile Organic Compounds (VOCs) and Liver Diseases

Analysis of Volatile Organic Compounds in Exhaled Air as a Non-invasive Biomarker for Liver Diseases

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01279356

Enrollment

160

Registered

2011-01-19

Start date

2011-02-28

Completion date

2012-08-31

Last updated

2011-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Keywords

Liver diseases, Volatile organic compounds, Inflammation, Oxidative stress, non-invasive tests

Brief summary

Liver diseases such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) and viral hepatitis have the potential to progress to cirrhosis and finally hepatocellular carcinoma (HCC). Early diagnosis and treatment of liver diseases is important since progression is likely and is associated with significant morbidity and mortality. However, in daily clinical practice no specific and non-invasive biomarkers are used for the diagnosis and follow-up of patients with liver diseases. It is known that patients with liver diseases produce compounds that can be excreted in breath as a consequence of metabolic processes, inflammation and/or oxidative stress. These are called volatile organic compounds (VOCs). Analysis of VOCs in exhaled air has been reported to provide valuable information in patients with chronic obstructive lung disease (COPD) and inflammatory bowel disease (IBD). Also, in patients with liver disease, exhaled VOCs have been detected. The investigators hypothesize that analysis of VOCs in exhaled air of patients with liver diseases can be used for diagnosis and follow-up.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Established diagnosis of liver diseases based on laboratory, radiological and histological characteristics * Age between 18 and 85 years

Exclusion criteria

* Inflammatory bowel disease * Chronic obstructive lung disease, lung cancer, asthma * Rheumatoid arthritis

Design outcomes

Primary

Measure	Time frame
To establish the validity of VOC analysis in exhaled air to discriminate between liver diseases and non-diseased controls	12 months

Secondary

Measure	Time frame
To compare the VOC profiles in exhaled air between various liver diseases	12 months
To compare the VOC analysis before, during and after therapeutic interventions in various liver diseases	12 months
To compare VOC profiles with systemic inflammatory and oxidative stress markers	12 months

Countries

Netherlands

Contacts

Primary ContactKirsten Pijls, MD

k.pijls@maastrichtuniversity.nl+31433882157

Outcome results